Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has proved helpful vigilantly but unsuccessfully to create a single therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination therapy in the therapy of multi-drug-resistant HIV have been closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of the past several shares of mine. The 1st CytoDyn post of mine, “CytoDyn: What to be able to Do When It’s Too Good In order to Be True?”, set away what follows prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a highly marketing image in the Uptick Newswire interview that I came away with a poor impression of the business.

Irony of irony, the poor opinion of mine of the company has grown steadily, though the disappointment has not been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger at the moment still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall mean as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the therapy as well as reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s payment of $3.5 zillion transfers ownership of the expertise as well as connected intellectual property coming from Progenics to CytoDyn, as well as roughly 25 million mg of majority drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 zillion) and the first brand new drug program endorsement ($5 million), as well as royalty payments of 5 % of net sales upon commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous indications and numerous therapies, it has this individual therapy in addition to a “broad pipeline of indications” since it puts it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially advantageous therapy in dozens of indications.

The opening banner of its on its site (below) shows an energetic organization with diverse interests albeit centered on leronlimab, several disease types, multiple publications in addition to multiple presentations.

Can all of it be smoke cigarettes and mirrors? That’s a question I have been asking myself from the very beginning of the interest of mine in this business. Judging by the multiples of a huge number of various responses on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m far from alone in this question.

CytoDyn is a traditional battleground, or possibly some could say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *